Thursday, 15 October 2026European Markets

SPBK 1 ØSTLANDET And SPBK 1 NORDMØRE Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(VIANEWS) - SPBK 1 ØSTLANDET (SPOL.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SPBK 1 ØSTLANDET (SPOL.OL) kr138.66 5.62% 12.18%
SPBK 1 NORDMØRE (SNOR.OL) kr124.00 5.56% 8.58%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SPBK 1 ØSTLANDET (SPOL.OL)

5.62% Forward Dividend Yield and 12.18% Return On Equity

SpareBank 1 Østlandet provides various financial products and services to individuals, businesses, the public sector, clubs, and societies. The company operates through Retail, Corporate, and Organisation Market and Capital Market segments. The Retail segment provides financial services comprising of savings, money transfer, insurance, accident prevention, financing, money transfer, capital, and investment management services. The Corporate segment offers interest rate, currency hedging, and investment related services, as well as insurance services for property. The Organisation Market and Capital Market segment provides risk based advisory solutions to high-net-worth individuals and corporates, as well as engages in foreign currency services. SpareBank 1 Østlandet was founded in 1845 and is headquartered in Hamar, Norway. SpareBank 1 Østlandet operates as a subsidiary of Sparebankstiftelsen Hedmark.

Earnings Per Share

As for profitability, SPBK 1 ØSTLANDET has a trailing twelve months EPS of kr14.23.

PE Ratio

SPBK 1 ØSTLANDET has a trailing twelve months price to earnings ratio of 9.74. Meaning, the purchaser of the share is investing kr9.74 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.18%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is 28.8% and 58%, respectively.

Volume

Today's last reported volume for SPBK 1 ØSTLANDET is 13015 which is 63.83% below its average volume of 35988.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SPBK 1 ØSTLANDET's stock is considered to be oversold (<=20).

More news about SPBK 1 ØSTLANDET.

2. SPBK 1 NORDMØRE (SNOR.OL)

5.56% Forward Dividend Yield and 8.58% Return On Equity

SpareBank 1 Nordmøre provides various banking services in Norway. The company provides business insurance products, including liability, work machine, condominium, car, bus, boat, cyber, crime, truck, property, commercial building, project, trailer, and transport insurance; personal insurance products, such as life, business, travel, and accidental insurance products; pension products; bank cards; payment and debt collection services; and mobile and online banking services. It also offers bank guarantees, operating credit products for agriculture, and factoring and leasing products and services, as well as savings and deposit accounts, refinancing, and mortgage services. The company was founded in 1835 and is based in Kristiansund, Norway. SpareBank 1 Nordmøre operates as a subsidiary of SpareBank 1 Gruppen AS.

Earnings Per Share

As for profitability, SPBK 1 NORDMØRE has a trailing twelve months EPS of kr13.79.

PE Ratio

SPBK 1 NORDMØRE has a trailing twelve months price to earnings ratio of 8.99. Meaning, the purchaser of the share is investing kr8.99 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.58%.

More news about SPBK 1 NORDMØRE.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com